Entity

Time filter

Source Type

Tianjin, China

Zhao X.,Beijing Tongren Hospital | Wu F.,Beijing Tongren Hospital | Jia S.,Capital Medical University | Qu P.,Dalian Medical University | And 5 more authors.
Clinical and Experimental Hypertension | Year: 2010

The purpose of this study is to compare the effects and safety of azelnidipine and amlodipine in Chinese essential hypertensive patients. Patients were randomized to receive administration of azelnidipine 816 mgday or amlodipine 2.55 mgday for 8 weeks. The blood pressure and pulse rate were evaluated in an outpatient clinic and by ambulatory blood pressure monitoring. There were 220 patients enrolled to the study. The blood pressure in both groups was decreased significantly (P < 0.001). Compared with amlodipine, the patients received azelnidipine had better response in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (P < 0.01). No significant changes of pulse rate were observed in either group. For the ambulatory blood pressure monitoring, both drugs had stable anti-hypertensive effects over 24 h. The troughpeak ratios of DBP for the azelnidipine and amlodipine groups were, respectively, 46 and 40. Adverse events occurred at 7.3 and 10.0, respectively in the azelnidipine and amlodipine groups (P 0.485). Headache and dizziness were observed at an incidence of more than 1 in both groups. Once-daily administration of azelnidipine effectively controlled blood pressure and had a stable action over 24 h. Azelnidipine had good safety and compliance similar to amlodipine. © 2010 Informa UK Ltd. Source


Zhao X.-L.,Academy of Military Medical Science | Chen W.-Q.,Academy of Military Medical Science | Shen C.-F.,U.S. Center for Disease Control and Prevention | Ji Y.,U.S. Center for Disease Control and Prevention | And 3 more authors.
Progress in Biochemistry and Biophysics | Year: 2011

To prepare human antibody to rabies virus with high neutralizing potency using ribosome display technology. The immunoglobulin heavy and light chain variable (VH, VL) genes were prepared with the peripheral blood lymphocytes from three volunteers immunized with rabies virus vaccine by PCR. The genes encoding scFv fragments were prepared by randomly combining VH and VL genes by SOE PCR. Rabies virus glycoprotein (RVGp) specific scFv genes were selected over five cycles of ribosome display. The isolated scFv genes were cloned into pET22b(+)/BL21(DE3), from which soluble scFv fragments were prepared. The expressed products of selected clones were analyzed by ELISA for isolating the positive clones. To improve the stability of obtained scFvs, VH-Lc-VK were constructed and characterized. A human scFv gene library with 6.2×10 12 numbers used for ribosome display was constructed. Among the 180 selected clones, four clones RB24, RB71, RB109 and RB156 which exhibited the highest ELISA signals were isolated. The analysis of their sequences showed that they were new human immunoglobulin V genes to RVGp. And the reconstructed VH-Lc-VK antibody fragments can recognize RVGp specifically and antagonize the cytolytic effect of rabies virus on Vero cells. The prepared VH-Lc-VKfragments to RVGp will be useful for preparing engineering antibodies with high affinity against rabies virus. Ribosome display is a rapid means of generating fully human antibody fragments in vitro. Source


Yan L.-R.,Peking Union Medical College | Li Y.-S.,Peking Union Medical College | Chen G.-L.,Peking Union Medical College | Wang L.,Peking Union Medical College | And 7 more authors.
Journal of Cardiovascular Pharmacology | Year: 2012

This is a multicenter, randomized, double-blind, parallel-controlled study, conducted in Chinese patients with mild to moderate essential hypertension. After a 2-week washout period, 236 eligible patients were randomly to receive aranidipine 5-10 mg/d (n = 118) or amlodipine 5-10 mg/d (n = 118) for 10 weeks. The blood pressure and heart rate were evaluated in outpatient clinics, and ambulatory blood pressure monitoring was performed in 24 patients in each group. The blood pressure was significantly decreased in both groups. Compared with amlodipine, the patients who received aranidipine had less response in blood pressure (P < 0.01). The trough/peak ratios of diastolic blood pressure in aranidipine and amlodipine groups were 0.57 ± 0.20 and 0.68 ± 0.19, respectively (P = 0.119). Adverse events occurred at 11.86% and 7.63% in the aranidipine and amlodipine groups, respectively (P = 0.348). Headache was observed at an incidence of >3.0% in both groups, and the serum glucose and lipid profile had no significant change in the amlodipine group. In conclusion, once-daily administration of aranidipine (5-10 mg) effectively controlled blood pressure, and the short-term treatment might result in it being less effective than amlodipine. It had a stable action over 24-hour period, and the mechanism of that is not yet clear. Aranidipine had a good safety similar to that of amlodipine. © 2012 by Lippincott Williams & Wilkins. Source


Liu C.,309th Hospital of PLA | Tu Y.,PLA Fourth Military Medical University | Yuan J.,PLA Fourth Military Medical University | Mao X.,254th Hospital of PLA | And 5 more authors.
Journal of Biomedicine and Biotechnology | Year: 2012

Aim. To examine the expression of N-methylpurine-DNA glycosylase (MPG) gene and protein in glioma samples with different WHO grades and its association with patients' survival. Methods. Immunohistochemistry assay, quantitative real-time PCR and Western blot analysis were carried out to investigate the expression of MPG gene and protein in 128 glioma and 10 non-neoplastic brain tissues. Results. MPG gene expression level in glioma tissues was significantly higher than that in non-neoplastic brain tissues (P<0.001). Immunohistochemistry also showed that MPG protein was over-expressed in glioma tissues, which was consistent with the resutls of Western blot analysis. Additionally, the expression levels of MPG gene and protein both increase from grade I to grade IV glioma according to the results of real-time PCR, immunohistochemistry and western blot analysis. Moreover, the survival rate of MPG-positive patients was significantly lower than that of MPG-negative patients (P<0.001). We further confirmed that the over-expression of MPG was a significant and independent prognostic indicator in glioma by multivariate analysis (P<0.001). Conclusions. Our data showed the over-expression of MPG gene and protein in human gliomas, and also suggested for the first time that MPG be an unfavorable independent prognostic indicator for glioma patients. Copyright 2012 Ce Liu et al. Source


Wang L.,PLA Fourth Military Medical University | He S.,PLA Fourth Military Medical University | Yuan J.,PLA Fourth Military Medical University | Mao X.,254th Hospital of PLA | And 4 more authors.
Medical Oncology | Year: 2012

SOX9 belongs to the SOX (Sry-related high-mobility group box) family and acts as a transcription factor that plays a central role in the development and differentiation of multiple cell lineages. Recent studies have demonstrated that SOX9 is required for the carcinogenesis in several cancer types. The aim of this study was to investigate the clinicopathological significance of SOX9 expression in human malignant glioma. SOX9 mRNA expression was detected by real-time quantitative RT-PCR assay in glioma and nonneoplastic brain tissues. Then, the association of SOX9 mRNA expression with clinicopathological factors or prognosis of glioma patients was statistically analyzed. In addition, the small interfering RNA was used to knockdown SOX9 expression in a glioma cell line and to analyze the effects of SOX9 inhibition on cell growth, cell cycle and apoptosis of glioma cell line. The expression level of SOX9 mRNA in glioma tissues was significantly higher than that in corresponding nonneoplastic brain tissues (P < 0.001). In addition, a high level of SOX9 mRNA expression was significantly more common in glioma tissues with advanced WHO grade than those with low grade (P = 0.02). The increased expression of SOX9 mRNA was also significantly correlated with low Karnofsky performance score (P = 0.008). Meanwhile, the disease-free and overall survival rates of patients with high SOX9 mRNA expression were obviously lower than those of patients with low SOX9 mRNA expression (both P = 0.01). Multivariate analysis showed that high SOX9 mRNA expression was an independent prognostic factor for glioma patients (P = 0.02). Moreover, the down-regulation of SOX9 could inhibit the cell growth, induce the cell arrest in G2/M phase of cell cycle and enhance the apoptosis in glioma cells. Our data suggest for the first time that the over-expression of SOX9 mRNA is closely associated with poor clinical outcome of patients with malignant gliomas, and targeting SOX9 may be a novel therapeutic strategy for this tumor. © 2012 Springer Science+Business Media, LLC. Source

Discover hidden collaborations